CHEK2 and breast neoplasm: Furthermore, the poor survival associated with the CHEK2 1100delC gene-expression signature suggests differential progression pathways in breast tumors with defective CHEK2. Our results converge to highlight the importance of the WNT pathway as a driver of tumorigenesis in breast tumors of CHEK2 1100delC-mutation carriers.